Mechanism of action of the nonlipophilic antiallergic drug eclazolast (REV 2871) in the inhibition of mediator release in a mast cell model

Inflammation Research

Volumn 48, Issue 11, 1999, Pages 569-574

  Fischer, M J E ^a   De Mol, N J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiallergic; Calcium; Eclazolast; Exocytosis; RBL 2H3

Indexed keywords

ANTIALLERGIC AGENT; ARACHIDONIC ACID; ASTEMIZOLE; BETA N ACETYLHEXOSAMINIDASE; CALCIUM; ECLAZOLAST; INOSITOL 1,4,5 TRISPHOSPHATE; MECLOZINE; OXATOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; EXOCYTOSIS; MAST CELL LEUKEMIA; NONHUMAN; RAT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; ARACHIDONIC ACID; BETA-N-ACETYLHEXOSAMINIDASE; CALCIUM CHANNELS; CATTLE; CELL LINE; ERYTHROCYTES; EXOCYTOSIS; FIBRONECTINS; HEMOLYSIS; HISTAMINE H1 ANTAGONISTS; INDICATORS AND REAGENTS; INFLAMMATION MEDIATORS; INOSITOL 1,4,5-TRISPHOSPHATE; LIPID BILAYERS; LIPOSOMES; MAST CELLS; OXAZOLES; RATS; RECEPTORS, FC; RECEPTORS, IGE; RECEPTORS, PURINERGIC P1;

EID: 0032721814     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050505     Document Type: Article

References (28)

1. Coutts SM, Khandwala A, Shoupe TS, Musser JH, Klunk LJ, Weinryb I. REV 2871 (CHBZ): A novel inhibitor of histamine release. Agents Actions 1986; 18: 318-24.
2. 1-receptor antagonists). J Allergy Clin Immunol 1992; 90: 705-15.
3. Lau HYA, Pearce FL. Effects of antihistamines on isolated rat peritoneal mast cells and on model membrane systems. Agents Actions 1990; 29: 151-61.
4. 1-antagonist derived anti-allergic drugs: Relation to lipophilicity and membrane effects. Inflamm Res 1995; 44: 92-7.
5. Coutts SM, Khandwala A, Weinryb I. REV 2871 (CHBZ): A potent antiallergic agent with a novel mechanism of action: 2. Studies on the mechanism of action. Biochem Pharmacol 1987; 36: 673-82.
6. Fischer MJE, Paulussen JJC, Roozendaal R, Tiemessen RC, de Mol NJ, Janssen LHM. Relation between effect on calcium pathways and membrane structure of a set of anti-allergies in FcεRI activated signal transduction. Inflamm Res 1996; 45: 564-73.
7. 2+ influx. Biochem Pharmacol 1998; 55: 1255-62.
8. Paulussen JJC, Fischer MJE, Zuidam NJ, van Miltenburg JC, de Mol NJ, Janssen LHM. Influence of the antiallergic drug oxatomide and derivatives on membrane structures: Relation with inhibition of calcium influx in rat basophilic leukemia cells. Biochem Pharmacol 1999; 57: 503-10.
9. Beaven M, Metzger H. Signal transduction by Fc receptors: The FcεRI case. Immunol Today 1993; 14: 222-6.
10. Paulussen JJC, Fischer MJE, Roclofsen EPW, Horbach DA, de Mol NJ, Janssen LHM. Oxatomide and derivatives as inhibitors of mediator release from a mast cell model; structure activity relationships. Drug Res 1996; 46: 496-501.
11. Biltonen RL, Lichtenberg D. The use of differential scanning calorimetry as a tool to characterize liposome preparations. Chem Phys Lipids 1993; 64: 129-49.
12. Paulussen JJC, Fischer MJE, Kok-van Esterik JAE, Tiemessen RC, de Mol NJ, Janssen LHM. Influence of the anti-allergic drug oxatomide on the signal transduction mechanism in a mast cell model. Eur J Pharmacol 1996; 312: 121-30.
13. Bominaar AA, Van Haastert PJM. Phospholipase C activity in Dictyostelium discoideum using endogenous nonradioactive phosphatidylinositol 4,5-bisphosphate as substrate. Meth Enzymol 1994; 238: 207-18.
14. 2+ channels and exocytosis. Eur J Pharmacol 1998; 350: 353-61.
15. Paulussen JJC, Fischer MJE, Roozendaal R, van der Heijden VS, van Dijken P, de Mol NJ, et al. Effects of oxatomide and derivatives on high affinity IgE receptor-activated signal transduction pathways in rat basophilic leukemia cells: Role of protein tyrosine hyperphosphorylation and inhibition of extracellular calcium influx. Biochem Pharmacol 1998; 56: 693-701.
16. 2+-ATPase. Proc Natl Acad Sci USA 1990; 87: 2466-70.
17. 2+ stores. Biochem J 1994; 304: 431-40.
18. Park DJ, Min HK, Rhee SG. IgE-induced tyrosine phosphorylation of phospholipase Cγ1 in rat basophilic leukemia cells. J Biol Chem 1991; 266: 24237-40.
19. Yasuda M, Hasunuma Y, Adachi H, Sekine C, Sakanishi T, Hashimoto H, et al. Expression and function of fibronectin binding integrins on rat mast cells. Int Immunol 1995; 7: 251-8.
20. Hamawy MM, Mergenhagen SE, Siraganian RP. Cell adherence to fibronectin and the aggregation of the high affinity immunoglobulin-E receptor synergistically regulate tyrosine phosphorylation of 105-115-kDa proteins. J Biol Chem 1993; 268: 5227-33.
21. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993; 268: 16887-90.
22. Khandwala A, Coutts SM, Pruss T, Jones H, Neiss E, Weinryb I. REV 2871 (CHBZ): A potent antiallergic agent with a novel mechanism of action: 1. Activity profile as an inhibitor of mediator release. Biochem Pharmacol 1987; 36: 663-72.
23. Berridge MJ. Capacitative calcium entry. Biochem J 1995; 312: 1-11.
24. Jouvin MHE, Adamczewski M, Numerof R, Letourneur O, Valle A, Kinet JP. Differential control of the tyrosine kinases lyn and syk by the two signalling chains of the high affinity immunoglobulin E receptor. J Biol Chem 1994; 269: 5918-25.
25. Kihara H, Siraganian RP. Src homology 2 domains of Syk and Lyn bind to tyrosine-phosphorylated subunits of the high affinity IgE receptor. J Biol Chem 1994; 269: 22427-32.
26. Scharenberg AM, Kinet JP. Initial events in FcεRI signal transduction. J Allergy Clin Immunol 1994; 94 Suppl 6: 1142-46.
27. Fischer MJE, Paulussen JJC, Kok-van Esterik JAE, van der Heijden VS, de Mol NJ, Janssen LHM. Effects of the anti-allergies astemizole and norastemizole on FcεRI receptor-mediated signal transduction. Eur J Pharmacol 1997; 322: 97-105.
28. Mohammadi M, Mcmahon G, Sun L, Tang C, Hirth P, Yeh BK, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997; 276: 955-60.